Brain Tumors 2022: From Biology to Therapy

confirmed for 2022

DAY 1 Wednesday, June 22, 2022
11:00 - 13:00 Registration and welcome coffee
13:00 - 14:00   Keynote lecture: John de Groot, University of California San Francisco, USA
The future of immunotherapy for glioma
14:00 - 17:20 Brain tumor pathobiology 
(chairs: Dolores Hambardzumyan, Bozena Kaminska)
14:00 - 14:35   Constantinos G. Hadjipanayis, Mount Sinai Icahn School of Medicine, USA
MEK pathway inhibition combined with 5-aminolevulinic acid- photodynamic therapy for the treatment of diffuse midline glioma
14:35 - 15:10   Martin van den Bent, Erasmus MC Cancer Institute, Netherlands
The landscape of clinical trial in glioma: recently completed and ongoing projects
15:10 - 15:40 COFFEE BREAK
15:40 - 16:15   Oren Becher, Mount Sinai Icahn School of Medicine, USA
Cellular heterogeneity in diffuse midline gliomas
16:15 - 16:50   Jacek Majewski, McGill University, Canada
Epigenomic landscapes of H3K27M mutant gliomas
16:50 - 17:20  

Oral presentations 
(3x10 min)

Rugile DragunaiteLithuanian University of Health Sciences, Kaunas, Lithuania
Investigation of m6A modified lncRNAs in different grade gliomas

Irati Hervas-Corpion, Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA) and Hospital Universitario Puerta del Mar, Cádiz, Spain
Implementation of histone H3 variants in the clinical diagnosis of low- and high-grade gliomas

Katarzyna B. Leszczynska, Nencki Institute ,Warsaw, Poland
Epigenetic modulation leads to the decrease of H3K27M oncohistone in pediatric high-grade gliomas

17:20 - 18:50 Poster session
DAY 2 Thursday, June 23, 2022
09:00 - 12:25 Glioma microenvironment, immunology and immunotherapy I
(chairs: Christel Herold-Mende, Aleksandra Ellert-Miklaszewska)
09:00 - 09:35   Bozena KaminskaNencki Institute, Warsaw, Poland
Immune microenvironment of glioma at single cell resolution
09:35 - 10:10   Dolores Hambardzumyan, Mount Sinai Icahn School of Medicine, USA
Glioblastoma subtype-specific heterogeneity of the immune microenvironment
10:10 - 10:40 COFFEE BREAK
10:40 - 11:15   Katrin Lamszus,Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Cancer immunoediting in malignant glioma - interactions between immune cells and tumor cells
11:15 - 11:50   Dieter Henrik Heiland, University of Freiburg, Germany
Spatiotemporal dynamics in the structural immunity of the glioblastoma microenvironment
11:50 - 12:25   Christel Herold-Mende, University of Heidelberg, Germany
Determinants of immune cell infiltration and immune responses in brain tumors
12:25 - 13:20 LUNCH BREAK
13:20 - 18:00 Brain tumor microenvironment, immunology and immunotherapy II
(chairs: Dinorah Friedman-Morvinski, Wiesława Grajkowska)
13:20 - 13:55   Hai-Kun Liu, German Cancer Research Center (DKFZ), Germany
Metabolic plasticity and cancer stem cell dormancy in glioblastoma
13:55 - 14:30   Alessandro MichelucciLuxembourg Institute of Health, Luxembourg
Revealing and harnessing tumour-associated microglia/macrophage heterogeneity in glioblastoma
14:30 - 15:05   Dinorah Friedmann-Morvinski, Tel Aviv University, Israel
Boosting CAR-T cell efficacy by modulation of the microenvironment in brain tumors
15:05 - 15:20   Sponsored: Agnieszka Ciesielska (Analityk | 10x Genomics)
Multiomic tumor microenvironment profiling using single cell and spatial trancriptomic solutions.
15:20 - 15:45 COFFEE BREAK
15:45 - 16:20   Houtan Noushmehr, Henry Ford Health, USA
Advances in epigenomic classification and liquid biopsy in glioma
16:20 - 16:55   Neta Erez, Tel Aviv University, Israel
Lipocalin-2 systemic signaling drives neuroinflammation and brain metastasis
16:55 - 17:30  

Oral presentations 
(3x10 min)

Lena Jassowicz, Heidelberg University Hospital, Heidelberg, Germany
Characterizing the Immune and Stromal Microenvironment of Breast Cancer Brain Metastases

Divsha Sher, Tel Aviv University, Israel
Transformation of Oligodendrocytes into Malignant Glioma Results in Cell of Origin-Specific Behavioral Deficits

Aditya Shroff, University College London, UK
Molecular profiling of a novel somatic murine mutant-IDH glioma model enables identification of high-risk mutant-IDH astrocytoma patient subgroup

20:00 - 23:00 Gala dinner (by invitation)
DAY 3 Friday, June 24, 2022
09:00 - 16:00 Brain tumor pathobiology, diagnostics & therapy
(chairs: Sergiusz Nawrocki)
09:00 - 09:35   Itay Tirosh, Weizmann Institute of Science, Israel
Intra-tumor heterogeneity and cellular hierarchies in glioma
09:35 - 10:10   Rolf Bjerkvig, University of Bergen, Norway, Luxemburg Institute of Health, Luxembrug
Glioma cell invasion: growth patterns and mechanistic insight
10:10 - 10:40 COFFEE BREAK
10:40 - 11:15   Guido Reifenberger, Heinrich Heine University of Dusseldorf, Germany
Recent advances in the molecular classification of gliomas – The new WHO classification 2021 and beyond
11:15 - 11:50  
Maria G. Castro, University of Michigan Medical School, USA
Epigenetic reprogramming of the tumor immune microenvironment in mutant IDH1 gliomas impacts myelopoiesis and reverses immunosuppression
11:50 - 12:05   Sponsored: Wojciech Bieniek (Perlan) 
Real-time analysis of cellular function with the Seahorse metabolic analyzer



13:05 - 13:40   Maciej Wiznerowicz, International Institute for Molecular Oncology, Poland

Cancer stemness defined by proteogenomics guides personalized therapies

13:40 - 14:15   Petra Hamerlik, AstraZeneca, UK
Functional interplay between aberrant DNA repair and cellular hierarchies in glioblastoma 
14:15 - 14:50   Agnieszka Bronisz, Mossakowski Medical Research Institute, Poland

Targeting hypoxia response for oncolytic virus immunotherapy

14:50 - 15:25   Waldemar Priebe, MD Anderson Cancer Center, University of Texas, Houston, USA
Drug discovery in academia: focus on CNS malignancies
15:25-16:00   Glenn Lesser, Wake Forest School of Medicine, USA

Trials and Tribulations: Reimagining Our Clinical Trial Approaches to CNS Malignancies

16:00 - 16:10 Closing remarks
16:10 - 19:00
Guided tour: Warsaw sightseeing (optional, free of charge)